Compare MLI & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLI | MDGL |
|---|---|---|
| Founded | 1917 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 12.0B |
| IPO Year | 1994 | 2005 |
| Metric | MLI | MDGL |
|---|---|---|
| Price | $121.10 | $520.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $130.00 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 552.8K | 349.8K |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | 29.19 | ★ 41.32 |
| EPS | ★ 6.86 | N/A |
| Revenue | ★ $4,178,547,000.00 | $180,133,000.00 |
| Revenue This Year | $10.66 | $58.39 |
| Revenue Next Year | $7.46 | $47.10 |
| P/E Ratio | $17.62 | ★ N/A |
| Revenue Growth | ★ 10.87 | N/A |
| 52 Week Low | $67.91 | $265.00 |
| 52 Week High | $139.29 | $615.00 |
| Indicator | MLI | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 65.61 | 62.15 |
| Support Level | $113.67 | $411.87 |
| Resistance Level | $139.29 | $610.00 |
| Average True Range (ATR) | 2.58 | 26.99 |
| MACD | 1.64 | 3.75 |
| Stochastic Oscillator | 94.98 | 64.35 |
Mueller Industries Inc makes copper, brass, aluminum, and plastic products. The company reports three business segments: piping systems, industrial metals, and climate. Piping systems, earning majority of the company's revenue, produces tubes, fittings, rods, valves, and other products and operates various firms world-wide. The industrial metals segment manufactures impacts and micro-gauge, brass rod and copper bar products, and brass value-added products. The climate segment produces items used to create temperature-control goods, including valves, twisted tubes, coaxial heat exchangers, and others. Numerous systems use the aforementioned products, including HVAC, water distribution, refrigeration, and automotive.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.